The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its n-terminally truncated primary metabolite GLP- 1 (9-36)amide

Peptides

Volumn 19, Issue 5, 1998, Pages 877-882

  Wettergren, A ^a   Wojdemann M ^a   Holst, Jens Juul ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Gastrointestinal hormone; GLP 1; Metabolism; Porglucagon

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCAGON LIKE PEPTIDE 1 [9-36] AMIDE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; GLUCAGON BLOOD LEVEL; HORMONE ACTION; HORMONE METABOLISM; HYPOGLYCEMIA; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STOMACH MOTILITY; SWINE;

EID: 0031863483     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(98)00020-5     Document Type: Article

References (29)

1. Adelhorst, K.; Hedegaard, B. B.; Knudsen, L. B.; Kirk, O. Structure activity studies of glucagon-like peptide-1. J. Biol. Chem. 269:6275-6278; 1994.
2. Bell, G. L.; Sanches-Pescador, R.; Laybourn, P. J.; Najarian, R. C. Exon duplication and divergence in human preproglucagon gene. Nature (London). 304:368-371; 1983.
3. Christophe, J.; Svoboda, M.; Dehaye, J. P. et al. The VIP/PHI/ secretin/helodermin/helospectin/GRF family: structure-function relationship of the natural peptides, their precursors and synthetic analogues tested in vitro on the receptors and adenylate cyclase in a panel of tissue membranes. In: Martinez J, ed. Peptide hormones as prohormones: prosessing, biological activity, pharmacology. Chichester: Ellis Horwood LDT; 1989:211-243.
4. Deacon, C. F.; Johnsen, A. H.; Holst, J. J. Degradation of glucagon-like peptide-1 by the human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80:952-957; 1995.
5. 2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 44:1126-1131; 1995.
6. Deacon, C. F.; Pridal, L.; Klarskov, L.; Olesen, M.; Holst, J. J. Glucagon-like peptide-1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am. J. Physiol. Endocrinol. Metab. 34:E458-E464; 1996.
7. Elliott, R. M.; Morgan, L. M.; Tredger, A.; Deacon, S.; Wright, J.; Marks, V. Glucagon-like peptide-1 and the glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J. Endocrinol. 38:159-166; 1993.
8. Gallwitz, B.; Schmidt, W. E.; Colon, J. M.; Creutzfeldt, W. Glucagon-like peptide-1 (7-36) amide: characterization of the domain responsible for the binding to its receptor on rat insulinoma RINm5F Cells. J. Mol. Endocrinol. 5:33-39; 1990.
9. Gutniak, M. K.; Larsson, H.; Heiber, S. J.; Juneskans, O. T.; Holst, J. J.; Ahren, B. Therapeutic levels of glucagon-like peptide-1 can be obtained in humans by a buccal tablet. Diabetes Care. 19:843-848; 1996.
10. Gutniak, M.; Ørskov, C.; Holst, J. J.; Ahren, B.; Efendic, S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N. Engl. J. Med. 326:1316-1322; 1992.
11. Herrmann, C.; Göke, R.; Richter, G.; Fehmann, H. C.; Arnold, R.; Göke, B. Glucagon-like peptide-1 and the glucose-dependent insulin-releasing peptide plasma levels in response to nutrients. Digestion. 56:117-126; 1995.
12. Holst, J. J. Glucagon-like peptide-1: a newly discovered gastrointestinal hormone. Gastroenterology. 107:1848-1855; 1994.
13. Holst, J. J.; Hansen, L.; Deacon, C. F. The GLP-1 receptor antagonist, GLP-1(9-36 amide), is a primary product of the intestinal L-cell. Diabetologia. 40:A27; 1997.
14. Holst, J. J.; Wettergren, A.; Wøjdemann, M.; Poulsen, S. S.; Ørskov, C. Glucagon-like peptide-1 (GLP-1): an important enterogastrone acting via the central nervous system. Hepatogastroenterology. 42:1071; 1995.
15. Knudsen, L. B.; Pridal, L. Glucagon like peptide 1 (9-36) amide is a major metabolite of glucagon like peptide 1 (7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur. J. Pharmacol. 318: 429-435; 1996.
16. Layer, P.; Holst, J. J.; Grandt, D.; Goebell, H. Ileal release of glucagon-like peptide-1 (GLP-1): association with inhibition of gastric acid secretion in humans. Dig. Dis. Sci. 40:1074-1082; 1995.
17. Mentlein, R.; Gallwitz, B.; Schmidt, W. E. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36 amide), and peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:829-835; 1993.
18. Miholic, J.; Ørskov, C.; Holst, J. J.; Kotzerke, J.; Meyer, H. J. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1), and reactive hypoglycaemia after total gastrectomy. Dig. Dis. Sci. 10:1361-1370; 1993.
19. Mojsov, S.; Heinrich, G.; Wilson, I. B.; Ravazzole, M.; Orci, L.; Habener, J. F. Preproglucagon gene expression in the pancreas and the intestine diversifies at the level of post-translationel processing. J. Biol. Chem. 261:11800-11889; 1986.
20. Nathan, D. M.; Schriber, E.; Fogel, H.; Mojsov, S.; Habener, J. F. Insulinotropic action of glucagon-like peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care. 15:270-276; 1992.
21. 2: a physiological inhibitor of gastric acid secretion in man. J. Endocrinol. 126:169-173; 1990.
22. Ørskov, C.; Holst, J. J.; Knuhtsen, S.; Baldissera, F. A. G.; Poulsen, S. S.; Nielsen, O. V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gen, are secreted separately from the small intestine, but not the pancreas. Endocrinology. 119:1467-1475; 1986.
23. Ørskov, C.; Rabenhøj, L.; Kofod, H.; Wettergren, A.; Holst, J. J. Production and secretion of the amidated and glycine-extended glucagon-like peptide-1 (GLP-1) in man. Diabetes. 43:535-539; 1994.
24. Ørskov, C.; Holst, J. J.; Poulsen, S. S.; Kirkegaard, P. Pancreatic and intestinal processing of the proglucagon in man. Diabetologia. 30:874-881; 1987.
25. Ørskov, C.; Wettergren, A.; Holst, J. J. Secretion of the incretin hormones glucagon-like peptide-1 and the gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 31:665-670; 1996.
26. Schjoldager, B. G. T.; Mortensen, P. E.; Christiansen, J.; Ørskov, C.; Holst, J. J. GLP-1 (glucagon-like peptide-1) and the truncated GLP-1, fragments of the human proglucagon, inhibit gastric acid secretion in humans. Dig. Dis. Sci. 34:703-708; 1989.
27. Wettergren, A.; Maina, P.; Boesby, S.; Holst, J. J. Glucagon-like peptide-1 7-36 amide and the peptide YY have additive inhibitory effects on gastric acid secretion in man. Scand. J. Gastroenterol. 32:552-555; 1997.
28. Wettergren, A.; Petersen, H.; Ørskov, C.; Christiansen, J.; Sheikh, P.; Holst, J. J. Glucagon-like peptide-1 7-36 amide and the peptide YY from the L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand. J. Gastroenterol. 29:501-505; 1994.
29. Wettergren, A.; Schjoldager, B.; Mortensen, P. E.; Myhre, J.; Christiansen, J.; Holst, J. J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic function in man. Dig. Dis. Sci. 4:665-673; 1993.